EUVIMEDEUVIMED entdecken
Vergleichsstudie

18F-NOTA-NFB PET/MRI in glioma recurrence: comparison with 11C-methionine PET/MRI and contrast-enhanced MRI

Zhenwei Du, Yi Luo, Jinju Sun, He Long, Jianping You, Xin Li, Lunshan Xu, Weiguo Zhang, Xiao Chen

Journal of Neuro-Oncology · 2025

DOI: 10.1007/s11060-025-05159-x ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Neuro-Oncology, 2025. Verfasst von Zhenwei Du und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Daping Hospital, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Glioma, Magnetic Resonance Imaging, Brain Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Science and Technology Innovation Ability Enhancement Project of Army Medical University, Chongqing Clinical Research Centre of Imaging and Nuclear Medicine, Natural Science Foundation of Chongqing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To investigate the clinical utility of 18F-NOTA-NFB PET/MRI relative to 11C-methionine (11C-MET) PET/MRI and contrast-enhanced MRI (CE-MRI) for glioma recurrence detection. METHODS: Patients with suspected recurrence of glioma were prospectively enrolled. All patients underwent paired 18F-NOTA-NFB and 11C-MET PET/MRI. Diagnostic efficiency of glioma recurrence detection by different imaging methods were assessed and compared. The suspected lesions showed via 18F-NOTA-NFB and 11C-MET PET/MRI were compared by SUVmax and tumor-to-background ratio (TBR). The diagnostic performance of 18F-NOTA-NFB and 11C-MET SUVmax/TBR was tested by receiver operating characteristic curve. RESULTS: Thirty-eight patients with suspected recurrent glioma were included, with 28 positive for recurrent gliomas and 10 negative for recurrence which were confirmed by the pathology or clinical follow-up. For visual assessment, the accuracy and specificity of 18F-NOTA-NFB PET were equivalent to 11C-MET PET (accuracy: 92.11% vs. 94.74%, P = 1.00; specificity: 70.00% vs. 80.00%, P = 1.00) and higher than CE-MRI (accuracy: 92.11% vs. 76.32%, P = 0.031; specificity: 70.00% vs. 10.00%, P = 0.031). For quantitative analysis, in recurrent gliomas, 18F-NOTA-NFB PET revealed higher SUVmax (P = 0.007) and TBR (P = 0.002) than treatment-related effects, with higher TBR for recurrence than that of 11C-MET (P < 0.001). Although 11C-MET SUVmax had the highest AUC of 0.911 for detecting glioma recurrence, but with no significant difference relative to 11C-MET TBR (AUC = 0.889, P = 0.75), 18F-NOTA-NFB SUVmax (AUC = 0.793, P = 0.32), and 18F-NOTA-NFB TBR (AUC = 0.829, P = 0.42). CONCLUSION: The diagnostic efficacy of 18F-NOTA-NFB PET or PET/MRI performed equivalent to 11C-MET PET or PET/MRI, and better than CE-MRI for diagnosis of recurrent gliomas. Compared to 11C-MET, 18F-NOTA-NFB PET/MRI exhibited higher TBR, giving advantages in glioma delineation that might provide valuable information for making treatment strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaMagnetic Resonance ImagingBrain NeoplasmsNeoplasm Recurrence, LocalPositron-Emission TomographyHumansFemaleMaleMethionineMiddle AgedAdultAgedContrast MediaCarbon RadioisotopesProspective StudiesRadiopharmaceuticalsMultimodal ImagingYoung AdultHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

11C-methionine18F-NOTA-NFBCXCR4GliomaPET/MRI

Substanzen

MethionineContrast MediaCarbon Radioisotopescarbon-11 methionineRadiopharmaceuticals1,4,7-triazacyclononane-N,N',N''-triacetic acidHeterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Daping Hospital, Army Medical University, Chongqing, China.
  • Department of Medical Engineering, Daping Hospital, Army Medical University, Chongqing, China.
  • Department of Infectious Diseases, Southwest Hospital, Army Medical University, Chongqing, China.
  • Department of Neurosurgery, Daping Hospital, Army Medical University, Chongqing, China. xuliu559@163.com.
  • Department of Radiology, Daping Hospital, Army Medical University, Chongqing, China. wgzhang01@163.com.
  • Chongqing Clinical Research Center for Imaging and Nuclear Medicine, Chongqing, China. wgzhang01@163.com.

Förderung

  • Science and Technology Innovation Ability Enhancement Project of Army Medical University
  • Chongqing Clinical Research Centre of Imaging and Nuclear Medicine
  • Natural Science Foundation of Chongqing
  • Chongqing Science and Health Joint Medical Research Project-Young and Middle-aged High-level Talent Project
  • AI Medical Research Project of Army Medical Center

Zitieren

APA

Du, Z., Luo, Y., Sun, J., Long, H., You, J., Li, X., Xu, L., Zhang, W., & Chen, X. (2025). 18F-NOTA-NFB PET/MRI in glioma recurrence: comparison with 11C-methionine PET/MRI and contrast-enhanced MRI. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-025-05159-x

Vancouver

Du Z, Luo Y, Sun J, Long H, You J, Li X, et al. 18F-NOTA-NFB PET/MRI in glioma recurrence: comparison with 11C-methionine PET/MRI and contrast-enhanced MRI. Journal of Neuro-Oncology. 2025. doi:10.1007/s11060-025-05159-x

BibTeX
@article{Du2025,
  author = {Du, Zhenwei and Luo, Yi and Sun, Jinju and Long, He and You, Jianping and Li, Xin and Xu, Lunshan and Zhang, Weiguo and Chen, Xiao},
  title = {18F-NOTA-NFB PET/MRI in glioma recurrence: comparison with 11C-methionine PET/MRI and contrast-enhanced MRI},
  journal = {Journal of Neuro-Oncology},
  year = {2025},
  doi = {10.1007/s11060-025-05159-x}
}
Kostenlos starten →